联系方式:400-990-3999 / 邮箱:sales@xiyashiji.com
西亚试剂 —— 品质可靠,值得信赖
Restoration of Human Dystrophin Following Transplantation of Exon-Skipping-Engineered DMD Patient Stem Cells into Dystrophic Mice
Rachid Benchaouir,1 Mirella Meregalli,1 Andrea Farini,1 Giuseppe D'Antona,3 Marzia Belicchi,1 Aurélie Goyenvalle,4 Maurizio Battistelli,1 Nereo Bresolin,1 Roberto Bottinelli,3 Luis Garcia,4,5, and Yvan Torrente1,2,
1 Stem Cell Laboratory, Department of Neurological Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Centro Dino Ferrari, University of Milan, via F. Sforza 35, 20122 Milan, Italy
2 UNISTEM, Centro Interdipartimentale di Ricerca sulle Cellule Staminali, University of Milan, via Balzaretti 9, 20133 Milan, Italy
3 Department of Experimental Medicine, Human Physiology Unit, University of Pavia, via Forlanini 6, 27100 Pavia, Italy
4 Genethon-CNRS UMR 8115, Groupe Maladie de Duchenne, 1 bis Rue de l'Internatonale, 91000 Evry, France
Corresponding author
Yvan Torrente
Duchenne muscular dystrophy (DMD) is a hereditary disease caused by mutations that disrupt the dystrophin mRNA reading frame. In some cases, forced exclusion (skipping) of a single exon can restore the reading frame, giving rise to a shorter, but still functional, protein. In this study, we constructed lentiviral vectors expressing antisense oligonucleotides in order to induce an efficient exon skipping and to correct the initial frameshift caused by the DMD deletion of CD133+ stem cells. The intramuscular and intra-arterial delivery of genetically corrected CD133 expressing myogenic progenitors isolated from the blood and muscle of DMD patients results in a significant recovery of muscle morphology, function, and dystrophin expression in scid/mdx mice. These data demonstrate that autologous engrafting of blood or muscle-derived CD133+ cells, previously genetically modified to reexpress a functional dystrophin, represents a promising approach for DMD